GlassScriptPhysician profile
Mikel J Pride
NPI 1477785491
$3,599.97
in general payments reported to CMS, 2019-2025
26 companies · $960 in 2025
The $960 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $249 · 2020: $239 · 2021: $331 · 2022: $285 · 2023: $718 · 2024: $817 · 2025: $960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,495.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $822.72 | 2021-2025 | |
| Lilly USA, LLC | $464.85 | 2020-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $383.36 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $367.86 | 2022-2025 | Repatha, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $249.46 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $183.43 | 2025 | |
| Glaxosmithkline, LLC. | $141.07 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $133.13 | 2019-2021 | |
| Exact Sciences Corporation | $119.67 | 2024-2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $115.68 | 2021 | |
| Bausch Health US, LLC | $106.30 | 2019-2024 | Aplenzin, Wellbutrin |
| Pfizer INC. | $75.71 | 2023-2025 | |
| Gilead Sciences, INC. | $56.70 | 2020-2024 | |
| Dexcom, INC. | $54.89 | 2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $54.30 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $48.28 | 2024-2025 | Horizant |
| Pharmacosmos Therapeutics INC. | $36.60 | 2021 | |
| Eisai INC. | $36.59 | 2019 | |
| Abbott Laboratories | $33.53 | 2025 | Freestyle Libre 3 |
| Adlon Therapeutics L.P. | $25.68 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $17.18 | 2024 | |
| Dynavax Technologies Corporation | $16.75 | 2023 | Heplisav-B |
| Almatica Pharma LLC | $15.00 | 2022 | |
| Genentech USA, INC. | $15.00 | 2020 | |
| Sanofi Pasteur INC. | $14.62 | 2019 | |
| Phathom Pharmaceuticals, INC. | $11.61 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mikel Pride listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.